The Power of Bone Marrow Concentrate for Rotator Cuff Disorders

Rotator cuff disorders (RCDs) pose a significant and urgent challenge in sports medicine and orthopedics, particularly among aging populations. Common among swimmers, golfers, tennis players, and basketball players, RCDs primarily stem from traumatic injuries, tendon overuse, or a combination of both factors (Murray et al., 2016). A tear in the rotator cuff can lead to chronic pain, arm weakness, and limited mobility, affecting a staggering 30%-50% of the population over the age of 50 each year (Centeno et al., 2020). Unfortunately, surgical options and traditional non-invasive treatments of RCD, such as anti-inflammatory drugs, corticosteroid injections, and physical therapy, often provide inconsistent results and focus primarily on symptom relief rather than restoring full functionality of the rotator cuff.

However, the emergence of regenerative therapies, particularly autologous bone marrow concentrate (BMC) injections, offer a promising capability to restore the original tendon insertion site to normal. These therapies can enhance the healing of the rotator cuff tendon while reducing, preventing, or reversing fatty degeneration of the muscle (Murry et al., 2016). BMC has emerged as a promising treatment option due to its rich composition of cells, platelets, growth factors and proteins. Derived from bone marrow aspirate (BMA), these cells exhibit remarkable versatility and offer a significant advantage over other cell-based products by avoiding various immunogenic complications due to the autologous and isolated nature of the treatment (Centeno et al., 2015).

Hernigou et al. (2014) conducted a clinical trial to assess the efficacy of BMC as an adjunct therapy alongside rotator cuff arthroscopy repair. In the study group, forty-five RCD patients underwent surgery following an arthroscopic protocol supplemented with autologous cell therapy. The adjunct BMC treatment exhibited a 100% success rate, with all study group patients experiencing restored functionality and improved quality of the repaired surface within six months. A decade later, the BMC injection had effectively prevented further ruptures, with approximately 87% of treated patients still maintaining intact rotator cuffs. Using BMC injection as an adjunct therapy in standard rotator cuff repair significantly enhanced long-term healing outcomes and tendon integrity.

Even as a standalone treatment, BMC offers promising results for patients with RCD. While clinical trials on the standalone use of BMC injections for treating RCD have been limited, Centeno et al. (2015) conducted a study involving 102 patients affected by osteoarthritis or RCD who underwent the solitary injection treatment. The study yielded promising results, with patients reporting nearly a 50% improvement compared to baseline for functionality and pain three months after the injection. These preliminary findings following BMC injections indicate the astounding potential for a standalone injection treatment for patients with RCD.?

Beyond its powerful healing capabilities for patients, autologous BMC is practical, efficient, and easy to incorporate into a clinic’s treatment protocols. There is no need for an extensive cell culturing expansion process before surgical application, as bone marrow aspiration can be concentrated in less than 30 minutes (Hernigou et al., 2014). Celling Biosciences’ ART BMC Plus Collection for BMA concentration is top-of-the-line in efficiency, with limited sterile breaks and easy-to-use functionality, outshining its competitors in the concentration of cells produced. With advanced concentrative technologies integrated into an all-in-one device, the ART BMC Plus simplifies the production of higher cell counts compared to its competitors. This ensures that physicians can provide the most efficient and effective treatment for patients with RCD.

In conclusion, BMC injections represent a groundbreaking and innovative approach to addressing the challenges of RCD. Celling Biosciences’ ART BMC Plus stands at the forefront of this medical revolution, offering unparalleled efficiency and effectiveness in cell concentration. Featuring a thumbwheel that allows for self-selection within the stack and a subsequent integrated filter, the ART BMC Plus allows users to obtain a highly concentrated sample of growth factors and proteins. This unique filter forces cells through hollow, nonporous fibers, pushing out excess saline while the cells are further concentrated. With its state-of-the-art technology, limited sterile breaks, and elevated cell counts, the ART BMC Plus ensures that physicians provide their patients with the most advanced and effective treatment for RCD. Contact Parker Pruitt ([email protected] ) to embrace the future of regenerative medicine and deliver the highest standard of care for your patients combatting RCD.

?

References:

Centeno, C. J., Al-Sayegh, H., Bashir, J., Goodyear, S., & Freeman, M. D. (2015). A prospective?multi-site registry study of a specific protocol of autologous bone marrow concentrate for the treatment of shoulder rotator cuff tears and osteoarthritis. Journal of Pain Research, 8, 269-276. 10.2147/JPR.S80872 ?

Hernigou, P., Lachaniette, C. H. F., Delambre, J., Zilber, S., Duffiet, P., Chevallier, N., & Rouard, H.?(2014). Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. International Orthopaedics (SICOT), 38, 1811-1818. 10.1007/s00264-014-2391-1 ?

Murray, I. R., LaPrade, R. F., Musahl, V., et al. (2016). Biologic Treatments for Sports Injuries II Think?? Tank- Current Concepts, Future Research, and Barriers to Advancement, Part 2: Rotator Cuff. Orthopaedic Journal of Sports Medicine, 4(3). 10.1177/2325967116636586 ?